STABILISE SELECTIVE TREATMENT OF ATHEROSCLEROSIS: DARAPLADIB INIHIBITS LP-PLA2 WITH ANTI-INFLAMMATORY AND PLAQUE STABILISING EFFECTS

Name: STABILISE SELECTIVE TREATMENT OF ATHEROSCLEROSIS: DARAPLADIB INIHIBITS LP-PLA2 WITH ANTI-INFLAMMATORY AND PLAQUE STABILISING EFFECTS (US 77309541)
Creator: United States Patent and Trademark Office

USPTO (United States) · Serial 77309541

Status: abandoned
Status updated: 2 August 2010
Filing date: 22 October 2007
Registration date: -
Nice classification: 16, 42
Owner: Glaxo Group Limited
Owner country: -
Raw status code: 606

Authoritative source

The official US trademark record is at USPTO TSDR (serial 77309541) ↗. Where our data differs from the USPTO record, theirs is correct.

See methodology for refresh cadence + status normalisation. See sources for licensing.